---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-22-000123"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:08:37.509677+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma Q3 product revenue $29.6M, record; raises cash guidance to $110-120M

## Summary
- Net product revenue $29.6M, up 31% pro forma YoY; Gvoke $13.7M (+24%), Keveyis $13.4M, Recorlev $2.5M.
- Full-year net product revenue guidance tightened to $105-110M; year-end cash guidance raised to $110-120M.
- Net loss $21.8M ($0.16/share) for Q3; cash & investments $93.4M at Sept 30.
- Positive Phase 1 topline for subcutaneous levothyroxine (XP-8121); FDA Type C meeting requested.
- On track for $50M in synergies by year-end 2022 and cash flow breakeven by year-end 2023.

## SEC filing metadata
- accession: 0001867096-22-000123
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000123/0001867096-22-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000123/xers-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-22-000123
- JSON: https://secwatch.observer/filing/0001867096-22-000123.json
- Plain text: https://secwatch.observer/filing/0001867096-22-000123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.